Surface staining of bEnd.3 cells with anti-mouse Flk-1 (Avas12a1) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.
Contents: Biotin anti-mouse Flk-1 (CD309, VEGF-R2, VEGFR2, Ly-73) Catalog Number: 13-5821 Formulation: Phosphate buffer pH 7.2, 150 mM NaCl, 0.09% NaN3 Clone: Avas12a1 Host/Isotype: Rat IgG2a, κ Storage Conditions: Store at 4°C. DO NOT FREEZE.
Product Options
Cat. No.
Size
Price
Add Qty to Cart
13-5821-81
50 ug
13-5821-82
100 ug
13-5821-85
500 ug
Note: Several countries will continue to be supplied via distributors. Country specific prices may apply.
Flow Cytometry Product Notes: Test Sizes: To accommodate multicolor flow cytometry, eBioscience is in the process of reducing test size volumes from 20 µl to 5 µl. Please check your antibody vial for the recommended test size. Fluorochrome Replacements: eBioscience is in the process of replacing all Pacific Blue® and APC-Alexa Fluor® 750 conjugated products with eFluor™ 450 and APC-eFluor™ 780 conjugated products, respectively.
Description
The Avas12a1 monoclonal antibody reacts with mouse Flk-1, also known as vascular endothelial growth factor receptor 2 (VEGFR2). Flk-1 is a receptor tyrosine kinase involved in vascular endothelial tissue development and is expressed on endothelial cells during embryonic stages and some endothelial tissues in the adult.
Applications Reported
For research use only, not for diagnostic or therapeutic use. The Avas12a1 antibody has been reported for use in flow cytometric analysis.
Applications Tested
The Avas12a1 antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be used at less than or equal to 0.5 μg per million cells in a 100 μl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
References
Kataoka, H., N. Takakura, et al. (1997)."Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells." Dev Growth Differ 39(6): 729-40.
